Research with human participants

Overview of medical research in the Netherlands

thrombocyte function after elective CABG with CPB

No registrations found.

Download: PDF | XML
Ethical review
Positive opinion
Status
Pending
Health condition type
-
Study type
Observational non invasive

ID

NL-OMON27232

Source

Nationaal Trial Register

Brief title

thrombofuel CC

Health condition

platelet function (platjes functie), cardiac surgery (hart chirurgie), platelet function recovery (platejs funtcie herstel)

Sponsors and support

Primary sponsor :
Maastricht University Medical Center
Source(s) of monetary or material Support :
no external funding

Intervention

Outcome measures

Primary outcome

Multiple impedance electrode aggregometry (MEA- Multiplate multiple impedance aggregometry Dynabyte Medical, Munich, Germany), Light transmission aggregometry (LTA-platelet aggregometer PAR-4, Hart Biologicals Ltd., Hartlepool UK)

Secondary outcome

Clinical parameters of bleeding (blood loss and transfusion requirements within the first 24 hours postoperative).

Background summary

Microvascular bleeding following coronary artery bypass surgery with cardiopulmonary bypass is frequently associated with platelet count and platelet function abnormalities. Aim of the study is to investigate in an observational study the platelet functon using multiple electrode impedance aggregometry and light transmission aggrogometry.

Study objective

thrombocyte function recovers quickly after cardiopulmonary bypass.

Study design

before, immediately at the end and 24 hrs after CPB samples will be drawn and analyzed after a short period of rest (30-45 min).

Intervention

The use of cardiopulmonary bypass during elective coronary artery bypass operations.

Public
dept of anesthesiology
MUMC+
P.Debeyelaan 25


M.D. Lancé
Maastricht 6202 AZ
The Netherlands
marcus.lance@mumc.nl
Scientific
dept of anesthesiology
MUMC+
P.Debeyelaan 25


M.D. Lancé
Maastricht 6202 AZ
The Netherlands
marcus.lance@mumc.nl

Inclusion criteria

elective patients scheduled for CABG
more than 250.00 thrombocyte/mcl

Exclusion criteria

low thrombocyte count (below 250.000/mcl)
use of platelet inhibitors other tha aspirine
known thrombocytes dysfunction

Design

Study type :
Observational non invasive
Intervention model
:
Other
Allocation :
Non controlled trial
Masking :
Open (masking not used)
Control :
N/A , unknown

Recruitment

NL
Recruitment status
:
Pending
Start date (anticipated) :
Enrollment :
20
Type :
Anticipated

Positive opinion
Date :
Application type :
First submission

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID
NTR-new NL4093
NTR-old NTR4238
Other : METC-12-4-111
ISRCTN ISRCTN wordt niet meer aangevraagd.

Summary results

N/A